特雷维治疗

US · TRVI #2810 按市值排名上市于 2019

11.88 -0.23 -1.90%

实时 - 追踪5344个代码 - 心跳于38秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了2家。
机构持股总比例下降了1.3个百分点。

机构持股

机构持股比例: 106.25% -1.26pp
机构数量: 252 +2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund51.57%

VC/PE Fund29.77%

Hedge Fund18.94%

Public Company4.52%

Private Company0.87%

Individual/Insider0.70%

Government Pension Fund0.28%

Family Office/Trust0.18%

Insurance Company0.11%

主要股东截至 2026-06-30

New Enterprise Associates, Inc. 9.28% · 13.22M 股

FMR 8.82% · 12.56M 股

BlackRock 7.83% · 11.16M 股

Frazier Life Sciences Management, LP 6.98% · 9.94M 股

Vanguard Capital Management, LLC 4.47% · 6.37M 股

Wellington Management Group 3.99% · 5.68M 股

Vivo Capital, LLC 3.58% · 5.09M 股

Woodline Partners LP 2.86% · 4.08M 股

Vestal Point Capital, LP 2.18% · 3.10M 股

MPM BioImpact LLC 2.16% · 3.07M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 38次买入 · 12次卖出

姓名	职务	持股比例
David Meeker	Independent Chairperson	0.25%
Thomas Sciascia	Co-Founder & Chief Science Officer	0.16%
Jennifer Good	Chief Executive Officer	0.15%
Farrell Simon	Chief Commercial Officer	0.06%
Lisa Delfini	Chief Financial Officer	0.05%
Christopher Galletta	Controller & Chief Accounting Officer	0.02%
Anne VanLent	Independent Director	0.02%
Michael Heffernan	Lead Independent Director	0.00%
New Enterprise Associates, Inc.	--	--
James Cassella	Independent Director	--

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-14	Michael Heffernan	Lead Independent Director	Derivative Exercise and Sale	-39,473	$3.04–15.88
2026-06-02	Anne VanLent	Independent Director	Other Derivative Acquisition	+35,000	$13.45
2026-06-02	Dominick Colangelo	Independent Director	Other Derivative Acquisition	+35,000	$13.45
2026-06-02	Edward Mathers	Independent Director	Other Derivative Acquisition	+35,000	$13.45
2026-06-02	David Meeker	Independent Chairperson	Other Derivative Acquisition	+35,000	$13.45
2026-06-02	Michael Heffernan	Lead Independent Director	Other Derivative Acquisition	+35,000	$13.45
2026-02-18	James Cassella	Independent Director	Other Derivative Acquisition	+215,000	$10.56
2026-02-18	Jennifer Good	Chief Executive Officer	Other Derivative Acquisition	+675,000	$10.56
2026-02-18	Thomas Sciascia	Co-Founder & Chief Science Officer	Other Derivative Acquisition	+85,000	$10.56
2026-02-18	Christopher Galletta	Controller & Chief Accounting Officer	Other Derivative Acquisition	+35,000	$10.56
2026-02-18	Farrell Simon	Chief Commercial Officer	Other Derivative Acquisition	+160,000	$10.56
2026-01-07	David Hastings	Chief Financial Officer & Principal Financial Officer	Other Derivative Acquisition	+375,000	$11.21
2025-12-01	Christopher Galletta	Controller & Chief Accounting Officer	Derivative Exercise and Retained	+4,225	$0.51
2025-10-06	Lisa Delfini	Chief Financial Officer	Intent to Sell (Form 144)	-108,650	$9.50
2025-10-02	Lisa Delfini	Chief Financial Officer	Intent to Sell (Form 144)	-40,000	$9.67
2025-08-26	Lisa Delfini	Chief Financial Officer	Intent to Sell (Form 144)	-312,855	$8.09
2025-06-10	Anne VanLent	Independent Director	Other Derivative Acquisition	+45,000	$6.25
2025-06-10	Dominick Colangelo	Independent Director	Other Derivative Acquisition	+45,000	$6.25
2025-06-10	Edward Mathers	Independent Director	Other Derivative Acquisition	+45,000	$6.25
2025-06-10	David Meeker	Independent Chairperson	Other Derivative Acquisition	+45,000	$6.25

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。